CRISPR–Cas9 mediated repression of BACE1 for amyloid-beta reduction in early-stage Alzheimer’s disease: A meta-analysis

Authors

  • Atta Ur Rehman Khan Allama Iqbal Teaching Hospital, Dera Ghazi Khan Pakistan
  • Safdar Manzoor Allama Iqbal Teaching Hospital, Dera Ghazi Khan Pakistan
  • Muhammad Sarmad Allama Iqbal Teaching Hospital, Dera Ghazi Khan Pakistan
  • Muhammad Rizwan Anwar Allama Iqbal Teaching Hospital, Dera Ghazi Khan Pakistan

DOI:

https://doi.org/10.55629/pakjpathol.v36i3.942

Abstract

Objective: To assess the efficacy of CRISPR–Cas9-mediated repression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in reducing amyloid-beta (Aβ) accumulation, neuropathological changes, and cognitive deficits in preclinical Alzheimer’s disease (AD) models.

Data Sources: A systematic search (2017–2024) was conducted in PubMed, Scopus, Web of Science, and Google Scholar, following PRISMA 2020 guidelines.

Study Selection: Ten preclinical studies using rodent or neuronal AD models with CRISPR–Cas9 or CRISPR interference targeting BACE1 were included.

Data Extraction: Extracted data included Aβ₄₀/₄₂ levels, BACE1 expression, plaque burden, neuronal integrity, neuroinflammation, and cognitive performance.

Data Synthesis: Meta-analysis (RevMan 5.4, STATA 17) showed significant reductions in Aβ₄₀/₄₂ (SMD = –1.45), BACE1 expression (SMD = –1.73), and plaque burden (SMD = –1.38). Qualitative findings indicated improved neuronal survival, reduced inflammation, and cognitive benefits.

Conclusions: CRISPR–Cas9 repression of BACE1 effectively attenuates amyloid pathology and supports cognitive improvements in preclinical AD models, underscoring its promise for translational CRISPR-based therapies.

Keywords: Alzheimer’s Disease, CRISPR, BACE1, Amyloid-beta, Meta-analysis, Gene editing.

References

DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019; 14(1): 32. DOI: https://doi.org/10.1186/s13024-019-0333-5.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016; 8(6): 595–608. DOI: https://doi.org/10.15252/emmm.201606210

Wang Q, Xiao B, Cui S, Song H, Qian Y, Dong L, et al. Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis Model Mech. 2014; 7(12): 1385–95.

DOI: https://doi.org/10.1242/dmm.018218

Morroni F, Caccamo A. Advances and challenges in gene therapy for Alzheimer’s disease. J Alzheimers Dis. 2024; 101(S1): S417–S431. DOI: https://doi.org/10.3233/JAD-230783

Bahn G, Park J-S, Yun UJ, Lee YJ, Choi Y, Park JS, et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models. Proc Natl Acad Sci USA. 2019; 116(25): 12516–23. DOI: https://doi.org/10.1073/pnas.1819541116

Barman NC, Khan NM, Islam M, Nain Z, Roy RK, Haque A, Barman SK. CRISPR-Cas9: A promising genome editing therapeutic tool for Alzheimer’s disease-A narrative review. Neurol Ther. 2020; 9(2):419–34. DOI: https://doi.org/10.1007/s40120-020-00218-z

Liu D, Zhang H, Liu C, Liu J, Liu Y, Bai N, et al. Systematic review and meta-analysis of the association between ABCA7 common variants and Alzheimer’s disease in non-Hispanic White and Asian cohorts. Front Aging Neurosci. 2024; 16: 1406573. DOI: https://doi.org/10.3389/fnagi.2024.1406573

Lu L, Yu X, Cai Y, Sun M, Yang H. Application of CRISPR/Cas9 in Alzheimer’s disease. Front Neurosci. 2021; 15: 803894. DOI: https://doi.org/10.3389/fnins.2021.803894.

Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, et al. CRISPR/Cas9 gene editing: New hope for Alzheimer’s disease therapeutics. J Adv Res. 2022; 40: 207–21. DOI: https://doi.org/10.1016/j.jare.2021.07.001.

Raffaele I, Cipriano GL, Anchesi I, Oddo S, Silvestro S. CRISPR/Cas9 and iPSC-based therapeutic approaches in Alzheimer’s disease. Antioxidants (Basel). 2025; 14(7): 781. DOI: https://doi.org/10.3390/antiox14070781.

Inoue K, Oliveira LM, Abeliovich A. CRISPR transcriptional activation analysis unmasks an occult γ-secretase processivity defect in familial Alzheimer’s disease skin fibroblasts. Cell Rep. 2017; 21(7): 1727–36. DOI: https://doi.org/10.1016/j.celrep.2017.10.075

Khan MS, Qureshi N, Khan R, Son Y-O, Maqbool T. CRISPR/Cas9-Based therapeutics as a promising strategy for management of Alzheimer’s disease: progress and prospects. Front Cell Neurosci. 2025; 19: 1578138.

DOI: https://doi.org/10.3389/fncel.2025.1578138

Asanomi Y, Kimura T, Shimoda N, Shigemizu D, Niida S, Ozaki K. CRISPR/Cas9-mediated knock-in cells of the late-onset alzheimer’s disease-risk variant, SHARPIN G186R, reveal reduced NF-κB pathway and accelerated Aβ secretion. J Hum Genet. 2024; 69(5): 171–6. DOI: https://doi.org/10.1038/s10038-024-01224-x.

Jiang H, Tang M, Xu Z, Wang Y, Li M, Zheng S, et al. CRISPR/Cas9 system and its applications in nervous system diseases. Genes Dis. 2024; 11(2): 675–86. DOI: https://doi.org/10.1016/j.gendis.2023.03.017

Monteiro AR, Barbosa DJ, Remião F, Silva R. Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023; 211: 115522.

DOI: https://doi.org/10.1016/j.bcp.2023.115522

Du Y, Zhao Y, Li C, Zheng Q, Tian J, Li Z, et al. Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes. J Exp Med. 2018; 215(6): 1665–77. DOI: https://doi.org/10.1084/jem.20172209.

Adji AS, Widjaja JS, Wardani VAK, Muhammad AH, Handajani F, Putra HBP, et al. A review of CRISPR Cas9 for Alzheimer’s disease: Treatment strategies and could target APOE e4, APP, and PSEN-1 gene using CRISPR cas9 prevent the patient from Alzheimer’s disease? Open Access Maced J Med Sci. 2022; 10(F): 745–57. DOI: https://doi.org/10.3889/oamjms.2022.9053

Rahimi A, Sameei P, Mousavi S, Ghaderi K, Hassani A, Hassani S, Alipour S. Application of CRISPR/Cas9 system in the treatment of Alzheimer’s disease and neurodegenerative diseases. Mol Neurobiol. 2024; 61(11): 9416–31. DOI: https://doi.org/10.1007/s12035-024-04143-2.

Tripathi S, Sharma Y, Rane R, Kumar D. CRISPR/Cas9 gene editing: A novel approach towards Alzheimer’s disease treatment. CNS Neurol Disord Drug Targets. 2024; 23(12): 1405-24. DOI: https://doi.org/10.2174/01187152732837 86240408034408

Sun J, Roy S. CRISPR Therapies for Alzheimer’s Disease. In: Tuszynski, M.H. (eds) Translational Neuroscience. Springer, Cham. DOI: https://doi.org/10.1007/978-3-031-89307-0_12

Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther. 2014; 6(9) :89.

DOI: https://doi.org/10.1186/s13195-014-0089-7.

Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213): 1258096. DOI: https://doi.org/10.1126/science.1258096

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2018; 378(18) :1691–703. DOI: https://doi.org/10.1056/NEJMoa1706441

Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020; 5(1): 1.

DOI: https://doi.org/10.1038/s41392-019-0089-y

Chen F, Fang S, Du Y, Ghosh A, Reed MN, Long Y, et al. CRISPR/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP/PS1 mice. Aging (Albany NY). 2021; 13(5): 6634–56.

DOI: https://doi.org/10.18632/aging.202501.

Shareena G, Viswalingam V, Rajput MS, Kumar D. CRISPR/Cas9 gene editing: A new hope for Alzheimer’s disease. In: Targeted Therapy for the Central Nervous System. Amsterdam: Elsevier; 2025. p. 301–23.

DOI: https://doi.org/10.1016/B978-0-443-23841-3.00014-5

Downloads

Published

30-09-2025

How to Cite

1.
Khan AUR, Manzoor S, Sarmad M, Anwar MR. CRISPR–Cas9 mediated repression of BACE1 for amyloid-beta reduction in early-stage Alzheimer’s disease: A meta-analysis . Pak J Pathol [Internet]. 2025 Sep. 30 [cited 2026 Nov. 17];36(3):252-61. Available from: https://pakjpath.com/index.php/Pak-J-Pathol/article/view/942